Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π³ΠΈΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ Π² Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ
ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ , ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ Π½Π°ΠΌΠΈ, ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ Π² Π³Π΅Π½Π°Ρ FVL ΠΈ FII ΡΠ²Π»ΡΡΡΡΡ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ’, ΠΈ ΡΡΠΎ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ ΠΎΠ½ΠΈ ΠΌΠΎΠ³ΡΡ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Ρ 50% Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΠ’. Π’Π°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΡ FVL ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ°, ΡΠ΅ΠΌ ΠΌΡΡΠ°ΡΠΈΡ FTI. ΠΠΌΠ΅ΡΡΠ΅ Ρ ΡΠ΅ΠΌ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΡ MTHFR (677Π‘-Π’) Π½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° Π΄Π°Π½Π½ΠΎΠΉ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΠΠ‘ΠΠ Π‘ΠΠΠ ΠΠ©ΠΠΠΠ
- ΠΠΠ©ΠΠ― Π₯ΠΠ ΠΠΠ’ΠΠ ΠΠ‘Π’ΠΠΠ Π ΠΠΠΠ’Π«. ΠΠΠ’Π£ΠΠΠ¬ΠΠΠ‘Π’Π¬ ΠΠ ΠΠΠΠΠΠ«
- ΠΠΠΠΠ 1. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΠ΅Π½ΠΎΠ·Π½ΡΠΉ ΡΡΠΎΠΌΠ±ΠΎΠ· ΠΊΠ°ΠΊ ΠΌΡΠ»ΡΡΠΈΡΠ°ΠΊΡΠΎΡΠ½Π°Ρ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ
- 1. 2. ΠΠ»Π°Π·ΠΌΠ΅Π½Π½ΡΠΉ ΡΠ°ΠΊΡΠΎΡ V ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΌΡΡΠ°ΡΠΈΡ Π³Π΅Π½Π° FVL, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°
- 1. 3. ΠΠ»Π°Π·ΠΌΠ΅Π½Π½ΡΠΉ ΡΠ°ΠΊΡΠΎΡ II ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΌΡΡΠ°ΡΠΈΡ Π³Π΅Π½Π° FII ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°
- 1. 4. Π’Π΅ΡΠΌΠΎΠ»Π°Π±ΠΈΠ»ΡΠ½ΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ ΠΌΠ΅ΡΠΈΠ»Π΅Π½ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡΠΎΠ»Π°Ρ ΡΠ΅Π΄ΡΠΊΡΠ°Π·Ρ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
- ΠΠ»Π°Π²Π° 2. ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ« ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ―
- 2. 1. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΎΠ±ΡΠ΅ΠΊΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
- 2. 2. ΠΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
- 2. 2. 1. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΠΠ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 2. 2. 2. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΠ΅ΠΉΠ΄Π΅Π½ΡΠΊΠΎΠΉ ΠΌΡΡΠ°ΡΠΈΠΈ Π³Π΅Π½Π° FV
- 2. 2. 3. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ 20210G-A Π³Π΅Π½Π° FII
- 2. 2. 4. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ 677Π‘-Π’ Π³Π΅Π½Π° MTHF
- 2. 3. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ²
- ΠΠ»Π°Π²Π° 3. Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π« ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ― Π ΠΠ₯ ΠΠΠ‘Π£ΠΠΠΠΠΠ
- 3. 1. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΠ΅ΡΠΎΠ΄Π° ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ FVL ΠΈ FII ΠΌΡΡΠ°ΡΠΈΠΉ
- 3. 2. ΠΠ΅ΠΉΠ΄Π΅Π½ΡΠΊΠ°Ρ ΠΌΡΡΠ°ΡΠΈΡ Π³Π΅Π½Π° FV
- 3. 2. 1. Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ FVL ΠΌΡΡΠ°ΡΠΈΠΈ Ρ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π°
- 3. 2. 2. Π§Π°ΡΡΠΎΡΠ° Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° FVL ΠΌΡΡΠ°ΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π²Π΅Π½ΠΎΠ·Π½ΡΠΌΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ
- 3. 2. 3. ΠΡΡΠ°ΡΠΈΡ FVL ΠΊΠ°ΠΊ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠΉ ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
- 3. 3. ΠΡΡΠ°ΡΠΈΡ 20210G-A Π³Π΅Π½Π° FII
- 3. 3. 1. Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ FII Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅
- 3. 3. 2. Π§Π°ΡΡΠΎΡΠ° Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΌΡΡΠ°ΡΠΈΠΈ FII Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π²Π΅Π½ΠΎΠ·Π½ΡΠΌΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ
- 3. 3. 3. ΠΡΡΠ°ΡΠΈΡ 20210G-A Π³Π΅Π½Π° FII ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
- 3. 4. ΠΡΡΠ°ΡΠΈΠΈ 677Π‘-Π’ Π³Π΅Π½Π° MTHFR
- 3. 4. 1. Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ 677Π‘-Π’ Π³Π΅Π½Π° MTHFR Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅
- 3. 4. 2. Π§Π°ΡΡΠΎΡΠ° Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΌΡΡΠ°ΡΠΈΠΈ 677Π‘-Π’ Π³Π΅Π½Π° MTHFR Π² Π³ΡΡΠΏΠΏΠ°Ρ ΡΠΈΡΠΊΠ° Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅
Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π³ΠΈΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ Π² Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΠ’Π£ΠΠΠ¬ΠΠΠ‘Π’Π¬ ΠΠ ΠΠΠΠΠΠ«.
ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ»ΠΈ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ Π±ΠΎΠ»ΡΡΠΎΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π΄Π»Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ.
ΠΠ½ΠΎΠ³ΠΎΡΠΈΡΠ»Π΅Π½Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ Π»Π΅Ρ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Ρ Π²ΡΡΡΠ½Π΅Π½ΠΈΡ ΡΠΎΠ»ΠΈ ΡΠ°ΠΊΠΈΡ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ Π΄Π΅ΡΠ΅ΠΊΡΠΎΠ², ΠΊΠ°ΠΊ Π°Π½ΠΎΠΌΠ°Π»ΠΈΡ ΡΠ°ΠΊΡΠΎΡΠ° V (ΠΠ΅ΠΉΠ΄Π΅Π½ΠΎΠ²ΡΠΊΠ°Ρ ΠΌΡΡΠ°ΡΠΈΡ) ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ (FVL) — Π³ΠΈΠΏΠ΅ΡΠ³ΠΎΠΌΠΎΡΠΈΡΡΠ΅ΠΈΠ½Π΅ΠΌΠΈΡ, Π²ΡΠ·ΡΠ²Π°Π΅ΠΌΠ°Ρ ΠΌΡΡΠ°ΡΠΈΠ΅ΠΉ 677Π‘-Π’ Π³Π΅Π½Π° ΡΠ΅ΡΠΌΠ΅Π½ΡΠ° ΠΌΠ΅ΡΠΈΠ»Π΅Π½ΡΠ΅ΡΡΠ°Π³Π°Π΄ΡΠΎΡΠΎΠ»Π°ΡΡΠ΅Π΄ΡΠΊΡΠ°Π·Ρ (MTHFR) — ΠΌΡΡΠ°ΡΠΈΡ 20210G-Π ΡΠ°ΠΊΡΠΎΡΠ° Π (FIT) ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ, Π² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΠΊΠΎΠ°Π³ΡΠ»ΠΎΠΏΠ°ΡΠΈΡΠΌ (18 Π7,30,61,62,6366,154).
Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΠΌΡΡΠ°ΡΠΈΠΈ ΠΏΠΎ ΡΠΊΠ°Π·Π°Π½Π½ΡΠΌ Π³Π΅Π½Π°ΠΌ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Π²ΠΎ Π²ΡΠ΅Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΡ ΠΠ²ΡΠΎΠΏΡ, ΠΠ·ΠΈΠΈ, ΠΠΌΠ΅ΡΠΈΠΊΠΈ ΠΈ ΠΠ½Π΄ΠΈΠΈ.
10,12,24,40,41,62,111,116,134,136,152,158,159,167.) ΠΠΎ ΠΈΠΌΠ΅ΡΡΠΈΠΌΡΡ Π΄Π°Π½Π½ΡΠΌ ΡΠ°ΡΡΠΎΡΠ° Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ ΠΌΡΡΠ°ΡΠΈΠΉ FVL, MTHFR ΠΈ FD Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ° Π²ΠΎ Π²ΡΠ΅Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΡ ΠΠ²ΡΠΎΠΏΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Ρ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ ΡΡΡΠ°Π½ Π‘ΡΠ΅Π΄ΠΈΠ·Π΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΌΠΎΡΡ ΠΈ Π°ΠΌΠ΅ΡΠΈΠΊΠ°Π½ΡΠ΅Π² Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ ΠΎΠΆΠ΄Π΅Π½ΠΈΡ (9,11,31,3 3,68,81,8 5,88,100,134,192) ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Ρ Π΄Π΅ΠΊΠ°Π΄Ρ, ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² FVL ΠΈ FII ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΡΠ²Π»ΡΡΡΡΡ ΡΠ΅ΡΡΠ΅Π·Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² (18,19,27,30,36,47,48,61,62,154,161,166,167,168,176) ΠΠ΅ΡΠ²ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠΈ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ², Π²ΡΠ·ΡΠ²Π°ΡΡΠΈΡ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΡ ΠΊ Π³Π°ΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ, Π±ΡΠ»ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Egeberg et al. Π² 1965 Π³. Π Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π² ΡΡΠΎΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΈ ΡΠ°Π·Π²ΠΈΠ²Π°Π»ΠΈΡΡ Π² ΡΠ°Π±ΠΎΡΠ°Ρ ΡΠ°ΠΊΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΠ°ΠΊ: Bertina etal., 1994; Dahlback et al., 1994; Franco et al., 1998; Pepe et al., 1997; Poort et al., 1996; Rees et al., 1996; Rosendaal et al., 1999; ΠΈ Π΄Ρ., ΠΊΠΎΡΠΎΡΡΠ΅ Π²ΡΡΠ²ΠΈΠ»ΠΈ FVL, MTHFR ΠΈ FD ΠΌΡΡΠ°ΡΠΈΠΈ ΠΈ ΠΏΡΠΈΡΠ»ΠΈ ΠΊ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΡΠΊΠ°Π·Π°Π½Π½ΡΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ ΡΠ²Π»ΡΡΡΡΡ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² (ΠΠ’) ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°ΡΡΡΡ Ρ Π±ΠΎΠ»Π΅Π΅, ΡΠ΅ΠΌ 50% Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΠ’.
ΠΠ½ΠΎΠ³ΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΠΈ ΡΠΎΠΎΠ±ΡΠ°ΡΡ, ΡΡΠΎ ΡΠ°ΡΡΠΎΡΠ° Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π΄Π°Π½Π½ΡΡ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π²Π°ΡΡΠΈΡΡΠ΅Ρ, ΡΡΠΎ, Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, ΡΠΊΠ°Π·ΡΠ²Π°Π΅ΡΡΡ Π½Π° ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΈΡ ΡΡΠ°ΡΡΠΈΡ Π² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠ΅ (27,50,81Π1129).
Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ ΠΊΠ°ΠΊ Π½Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠ² FVL, MTHFR ΠΈ FIT, ΡΠ°ΠΊ ΠΈ Π½Π° ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ Ρ Π²Π΅Π½ΠΎΠ·Π½ΡΠΌΠΈ ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ°Π΅Ρ ΠΎΡΠΎΠ±ΡΡ Π²Π°ΠΆΠ½ΠΎΡΡΡ Π΄Π»Ρ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ, ΠΈ Π² ΠΏΠ΅ΡΠ²ΡΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ Π΄Π»Ρ ΡΠ°Π½Π½Π΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³ΡΡΠΏΠΏ ΡΠΈΡΠΊΠ°.
Π ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π±ΠΎΡ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π³Π΅Π½Π°Ρ FVL, MTHFR ΠΈ FII Π½Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ. ΠΠΌΠ΅ΡΡΠ΅ Ρ ΡΠ΅ΠΌ, ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π΄Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ ΡΡΠ΅Π΄ΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π° Π² ΡΠ΅Π»ΠΎΠΌ ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ ΠΏΠΎ Π±ΠΎΡΡΠ±Π΅ Ρ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠ² FV, F13 ΠΈ MTHFR Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ ΠΈ Π΄ΡΡΠ³ΠΈΡ ΡΡΡΠ°Π½Π°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΡΡ ΠΈΠ»ΠΈ ΠΎΠΏΡΠΎΠ²Π΅ΡΠ³Π½ΡΡΡ ΠΈΠΌΠ΅ΡΡΠΈΠ΅ΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠ± Π°ΡΠ΅Π°Π»Π΅ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΈ ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ³ΡΡ ΠΏΠΎΡΠ»ΡΠΆΠΈΡΡ ΠΎΡΠ½ΠΎΠ²ΠΎΠΉ Π΄Π»Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ , Π±ΠΎΠ»Π΅Π΅ Π΄Π΅ΡΠ°Π»ΡΠ½ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ, ΠΊΠ°ΠΊ ΡΡΠ΅Π΄ΠΈ ΡΠ·ΠΊΠΎΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π³ΡΡΠΏΠΏ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ, ΡΠ°ΠΊ ΠΈ Π½Π° ΡΡΠΎΠ²Π½Π΅ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ ΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΠΌΠ΅Π½ΡΡΠΈΠ½ΡΡΠ² Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ ΠΈ ΠΠ°ΠΊΠ°Π²ΠΊΠ°Π·ΡΠ΅.
Π¦ΠΠΠ Π ΠΠΠΠΠ§Π ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ―.
Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ»ΠΎΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠ² FV (Leiden 1691G-A), FII (20210G-A) ΠΈ MTHFR (677Π‘-Π’) ΠΈ ΠΈΡ ΡΠΎΠ»ΠΈ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ’ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅. Π ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΡΠΈΠΌ Π±ΡΠ»ΠΈ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π·Π°Π΄Π°ΡΠΈ:
— ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ°ΡΡΠΎΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π΄Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ Π² ΡΠ΅Π»ΠΎΠΌ;
— Π²ΡΡΡΠ½ΠΈΡΡ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ ΡΠ°ΡΡΠΎΡ Π΄Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ ΡΡΠ΅Π΄ΠΈ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π³ΡΡΠΏΠΏ, Π½Π°ΡΠ΅Π»ΡΡΡΠΈΡ ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½;
— ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ°ΡΡΠΎΡΡ Π²ΡΡΠ΅ΡΠΊΠ°Π·Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π²Π΅Π½ΠΎΠ·Π½ΡΠΌΠΈ ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅;
— ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ) Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ FII ΠΈ FVL ΠΌΡΡΠ°ΡΠΈΠΉ Π² ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°.
ΠΠΠ£Π§ΠΠΠ― ΠΠΠΠΠΠΠ Π ΠΠΠΠ’Π«.
Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΠ°ΡΡΠΎΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠ² FV (Leiden 1691G-A), FII (20210G-A) ΠΈ MTHFR (677Π‘-Π’) Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅, ΠΊΠ°ΠΊ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅, ΡΠ°ΠΊ ΠΈ Π² Π³ΡΡΠΏΠΏΠ°Ρ ΡΠΈΡΠΊΠ° (Π²Π΅Π½ΠΎΠ·Π½ΡΠ΅ ΡΡΠΎΠΌΠ±ΠΎΠ·Ρ ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ).
ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π΄Π°Π½Π½ΡΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ Ρ ΡΠ°ΡΡΠΎΡΠ°ΠΌΠΈ: FVL -4−12,5%, Fn (20210G-A) — 1,25−3,3%, MTHFR (677Π’-Π’) — 2 — 4,3%. ΠΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΠΌΠΈ ΡΠ°ΡΡΠΎΡΡ Π΄Π°Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ: ΡΠ°ΡΡΠΎΡΠ° FVL ΠΌΡΡΠ°ΡΠΈΠΈ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½Π° Π΄ΠΎ 2 ΡΠ°Π·, Π² 3−4 ΡΠ°Π·Π° ΡΠ½ΠΈΠΆΠ΅Π½Π° ΡΠ°ΡΡΠΎΡΠ° Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡ ΠΏΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR (677Π‘-Π’), ΠΏΡΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠ½ΠΎΠΉ ΡΠ°ΡΡΠΎΡΠ΅ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΌΡΡΠ°ΡΠΈΠΈ ΠΠ-2%-3%.
ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ FV (Leiden 1691G-A), FII (20210G-A) ΠΈ MTHFR (677Π‘-Π’) ΠΌΡΡΠ°ΡΠΈΠΉ Ρ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π³ΡΡΠΏΠΏ, Π½Π°ΡΠ΅Π»ΡΡΡΠΈΡ ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½, Π½Π΅ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΈ.
ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ , ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ Π½Π°ΠΌΠΈ, ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ Π² Π³Π΅Π½Π°Ρ FVL ΠΈ FII ΡΠ²Π»ΡΡΡΡΡ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ’, ΠΈ ΡΡΠΎ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ ΠΎΠ½ΠΈ ΠΌΠΎΠ³ΡΡ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Ρ 50% Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΠ’. Π’Π°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΡ FVL ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ°, ΡΠ΅ΠΌ ΠΌΡΡΠ°ΡΠΈΡ FTI. ΠΠΌΠ΅ΡΡΠ΅ Ρ ΡΠ΅ΠΌ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΡ MTHFR (677Π‘-Π’) Π½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ.
Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ FVL, MTHFR ΠΈΠ»ΠΈ FII Π½Π΅ ΡΠ²Π»ΡΡΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ².
ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΠ¦Π Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ FII ΠΈ FVL Π² ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°.
ΠΠ ΠΠΠ’ΠΠ§ΠΠ‘ΠΠΠ― ΠΠΠΠ§ΠΠΠΠ‘Π’Π¬.
ΠΠ΅ΠΌΠΎΠ½ΡΡΡΠ°ΡΠΈΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΠ»ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° Π² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΠΠ’ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ ΠΈ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ± ΠΈΡ ΡΠ°ΡΡΠΎΡΠ΅ ΡΡΠ΅Π΄ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ Π²Π½ΠΎΡΠΈΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ ΠΏΡΠΈ ΠΠ’. ΠΠ΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, ΡΡΠΎ Π² ΡΠ»ΡΡΠ°ΡΡ Ρ ΠΎΡΡΠ³ΠΎΡΠ΅Π½Π½ΡΠΌ Π°Π½Π°ΠΌΠ½Π΅Π·ΠΎΠΌ ΠΏΠΎ ΠΠ’ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ FVL, ΡΠ°ΠΊ ΠΈ FII ΠΌΡΡΠ°ΡΠΈΠΉ Π΄Π»Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡΠΎΠ²ΠΊΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ°ΠΌΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΡ ΡΠΎΡΠΌ ΠΠ’ ΠΎΡΠ½ΠΎΠ²ΡΠ²Π°Π΅ΡΡΡ Π½Π° ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΠ¦Π ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π·Π° 8−10 ΡΠ°ΡΠΎΠ² ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΠΎΡΠ½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° FVL/FII ΠΌΡΡΠ°ΡΠΈΠΉ ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° (10−50 ΠΌΠΊΠ» ΠΊΡΠΎΠ²ΠΈ, Π²Π·ΡΡΠΎΠΉ Π½Π° Π»ΡΠ±ΠΎΠΌ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ΅).
ΠΠ‘ΠΠΠΠΠ«Π ΠΠΠΠΠΠΠΠΠ―, ΠΠ«ΠΠΠ‘ΠΠΠ«Π ΠΠ ΠΠΠ©ΠΠ’Π£.
1. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° ΡΠ°ΡΡΠΎΡΠ° Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΌΡΡΠ°ΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² FVL, FII, MTHFR Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ Π² ΡΠ΅Π»ΠΎΠΌ ΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΠΌΠΈ Π΄ΡΡΠ³ΠΈΡ ΡΡΡΠ°Π½.
2. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΠ°ΡΡΠΎΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL, FII ΠΈ MTHFR ΠΈ ΡΠ°ΡΡΠΎΡΡ ΠΈΡ Π°Π»Π»Π΅Π»Π΅ΠΉ FVL 1691 G, 1691 A, FII 20 010 G, MTHFR 677 Π‘ ΠΈ MTHFR 677 Π’ Π² ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΡΠ±ΠΎΡΠΊΠ°Ρ , Π½Π°ΡΠ΅Π»ΡΡΡΠΈΡ ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΡ ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π° — Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠ΅Π², Π»Π΅Π·Π³ΠΈΠ½ΠΎΠ², ΡΠ°Π»ΡΡΠ΅ΠΉ ΠΈ ΠΊΡΡΠ΄ΠΎΠ².
3. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π° ΡΠΎΠ»Ρ ΠΌΡΡΠ°ΡΠΈΠΉ FVL, FII ΠΈ MTHFR ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² .
4.Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½Ρ Π² ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΡΡ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π²ΡΡΠΎΠΊΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π°, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ΅Π³ΠΎ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ FVL, FII ΠΌΡΡΠ°ΡΠΈΠΈ ΠΏΡΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠ΅Π³ΠΎ ΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΈ Π΄ΠΎΡΠΎΠ³ΠΎΡΡΠΎΡΡΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΠ²ΠΎΠ².
Π²ΡΠ²ΠΎΠ΄Ρ.
1. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΠΌΡΡΠ°ΡΠΈΠΈ FVL, FII ΠΈ MTHFR Π²ΠΎ Π²ΡΠ΅Ρ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΡΠ±ΠΎΡΠΊΠ°Ρ — Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ, Π»Π΅Π·Π³ΠΈΠ½ΡΠΊΠΎΠΉ, ΠΊΡΡΠ΄ΡΠΊΠΎΠΉ, ΡΠ°Π»ΡΡΡΠΊΠΎΠΉ ΡΠΎ ΡΠ»Π΅Π΄ΡΡΡΠΈΠΌΠΈ ΡΠ°ΡΡΠΎΡΠ°ΠΌΠΈ: a) Π² Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL — 12,5%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FVL 1691G — 0,937, FVL 1691Π — 0063, ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FII — 1,25%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FΠ 20210G — 0,994, FII 20 210Π — 0,006- ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR — 44%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ MTHFR 677Π‘ — 0,76, MTHFR 677Π’-0,24- b) Π² Π»Π΅Π·Π³ΠΈΠ½ΡΠΊΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL — 11,5%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FVL 1691G — 0,942, FVL 1691Π — 0,058- ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FH -3,3%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FII 20210G — 0,984, FII 20 210Π — 0,016- ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR — 46%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ MTHFR 677Π‘ — 0,74, MTHFR 677 Π’ — 0,26- c) Π² ΠΊΡΡΠ΄ΡΠΊΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL — 10%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FVL 1691G -0,955, FVL 1691Π — 0,045, ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FII -2,5%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FII 20210G — 0,978, FH 20 210Π — 0,022- ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR 57%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ MTHFR 677Π‘ — 0,74−0,72, MTHFR 677 Π’ — 0,28- d) Π² ΡΠ°Π»ΡΡΡΠΊΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL — 4%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FVL 1691G — 0,98, FVL 1691Π — 0,020- ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ FU -2%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FII 20210G — 0,98, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FII 20 210Π — 0,02, ΡΠ°ΡΡΠΎΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR — 36%, ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ MTHFR 677Π‘ — 0,81, MTHFR 677Π’-0Π9.
2. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ, ΡΡΠΎ ΡΠ°Π·Π½ΠΈΡΠ° Π² ΡΠ°ΡΡΠΎΡΠ΅ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΌΡΡΠ°ΡΠΈΠΉ FVL, FIT, MTHFR ΠΈ ΡΠ°ΡΡΠΎΡΠ΅ Π°Π»Π»Π΅Π»Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΎΠΉ ΠΈ ΠΎΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π²ΡΠ±ΠΎΡΠΊΠ°ΠΌΠΈ ΠΈΠ· ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π³ΡΡΠΏΠΏ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°.
3. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ°ΡΡΠΎΡΠ° Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° FVL ΠΌΡΡΠ°ΡΠΈΠΈ Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ ΡΡΡΠ°Π½Π°Ρ . Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ ΡΠ°ΡΡΠΎΡΠ° Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡ ΠΏΠΎ MTHFR ΠΌΡΡΠ°ΡΠΈΠΈ Π².
ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Π² Π΄ΡΡΠ³ΠΈΡ ΡΡΡΠ°Π½Π°Ρ . ΠΡΠΎΡΠ΅Π½Ρ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΈ ΡΠ°ΡΡΠΎΡΠ° Π°Π»Π»Π΅Π»Ρ FII Π² ΠΠ·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½Π΅ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡ ΡΡΠ΅Π΄Π½Π΅Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΠΌ ΡΠ°ΡΡΠΎΡΠ°ΠΌ.
4. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL ΠΈ FII ΡΠ²Π»ΡΡΡΡΡ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΠ’. ΠΡΡΠ°ΡΠΈΡ FI3 ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΌΠ΅Π½Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ°, ΡΠ΅ΠΌ ΠΌΡΡΠ°ΡΠΈΡ FVL. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡ ΠΏΠΎ ΠΌΡΡΠ°ΡΠΈΠΈ MTHFR ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ.
5. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠ΅ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎ ΠΌΡΡΠ°ΡΠΈΠΉ FVL/FII ΠΈ FVL/MTHFR Π² Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ’, ΡΠ΅ΠΌ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΊΠ°ΠΆΠ΄ΠΎΠΉ ΠΌΡΡΠ°ΡΠΈΠΈ Π² ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎΡΡΠΈ. Π ΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Ρ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ FVL/FII Π³ΠΎΡΠ°Π·Π΄ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ FVL/MTHFR.
6. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ' Π½ΠΈ ΠΎΠ΄Π½Π° ΠΈΠ· ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² Π² Π²ΡΠ±ΠΎΡΠΊΠ΅ Π°Π·Π΅ΡΠ±Π°ΠΉΠ΄ΠΆΠ°Π½ΡΠ΅Π². ΠΠ΅ΠΊΠΎΡΠΎΡΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΌΡΡΠ°ΡΠΈΠΈ FII Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΠΌΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ.
7. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½Π° Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° Multiplex PCR — RFLP, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ°Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ ΠΌΡΡΠ°ΡΠΈΠΈ FVL ΠΈ FII ΠΏΡΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° (Π΄ΠΎ 10 ΠΌΠΊΠ» ΠΊΡΠΎΠ²ΠΈ) ΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠ°Ρ ΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΈ Π΄ΠΎΡΠΎΠ³ΠΎΡΡΠΎΡΡΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΠ²ΠΎΠ².
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ°ΡΠΊΠ°Π³Π°Π½ Π.Π‘. ΠΠ΅ΠΌΠΎΡΡΠ°Π³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ. Π., ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°. 1988.
- Π¨ΠΈΡΠΌΠ°Π½ Π€. ΠΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΡΠΎΠ²ΠΈ. Binom publiushers. 2000.
- Π‘Π½ΡΠ»Π» Π., ΠΠΎΡΡΠ΅ Π., ΠΡΡΠ΅Π½ΡΠΎΠ½ Π‘. Π‘ΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΠΎΡΡΡ ΡΠΊΠ°Π½Π΅ΠΉ. ΠΠΈΡ, Π., 1979.
- Π€ΠΎΠ³Π΅Π»Ρ Π€., ΠΠΎΡΡΠ»ΡΡΠΊΠΈ Π. ΠΠ΅Π½Π΅ΡΠΈΠΊΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. ΠΠΈΡ, Π., 1986, Ρ. 3, ΡΡΡ. 181 184.
- Adams Π., Smith P. D., Martin D., Thompson J. R., Lodwick D., Samani N. J. Genetic analysis of thermolabile methylene-tetrahydrofolate reductase as a risk factor for myocardial infarction. Quart. J."Med., 1998, v. 89, p. 437−444.
- Adrresino P., Mannucci P., Duca F., Corral J. Prothrombotic Genetic Risk Factors in Young Survivors of Myocardial Infarction. Blood, 1995, v. 94, p. 46−51.
- Allaart C. F., Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R.M. Increased risk of venous thrombosis in carriers of hereditary protein Π‘ deficiency defect. Lancet, 1993, v. 341, p. 134−138.
- Alhene-gelas M., Arnaud E., Nicaud V. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb. Haemost., 1999, v. 81, p. 506−510.
- Akar N., Akar E., Dalgin Sozuoz A., Omurliu K. Frequency of Factor V Leiden (1691G-A) mutation in Turkish population.Thromb. Haemost., 1997, v. 78, p. 1527−1528.
- Arruda V., Siquiera L., Chiapariani L., Coelho O., Mansur.A. Prevalence of the prothrombin gene variant 20 210 G-A with venous thrombosis and arterial disease. Blood, 1997, v.651, p. 960−961.
- H.Bancroft J., Schaefer L., Degen S. Characterization of the Alu- rich 5'- flanking region of the human prothrombin-encoding gene: Identification of a positive cis-acting element that regulates liver-specific expression. Gene, 1990, v. 95, p. 253 -264.
- Banfield D. K., MacGillivra T. A. Partial characterization of vertebrate prothrombin cDNAs: amplification and sequence analysis of the Π chain of thrombin from nine different species. Proc. Nac. Acad. Sci., 1992, v.89, p. 27 792 783.
- Bertina R.M., Briet E., Veltkamp J J. Variants of vitamin Π dependent coagulation factors. Acta Haemotologica, 1979, v. 62, p. 1−3.
- Bertina M. Hereditary protein S deficiency. Haemostasis, 1985, v. 15, p. 241−245.
- Bertina R., Koeleman Π., Koster Π’., Rosendaal F., Dirven R., de Ronde H., van der Velden P., Reitsma P. Mutation in Blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, v.369, p.64−67.
- Bertina R.M., Rosendaal F. R. Venous thrombosis the interaction of genes and environment. New Eng. J. Med., 1997, v.338, p. 1840−1841.
- Blajchman M. A., Austin R. C., Fernandez-Rachubinski F., Sheffield W. P. Molecular basis of inherited human antithrombin deficiency. Blood, 1992, v.80, p. 2159−2171.
- Board P. G., Coggan M., Pidcock M. E. Genetic heterogeneity of human prothrombin (FII). Ann. Hum. Genet., 1982, v. 46, p. 1−9.
- Bock S.C., Prochownik Π. V. Molecular genetic survey of 16 kindreds with hereditary antithrombin III deficiency. Blood, 1987, v. 70, p. 1273−1278.
- Boers G. Hyperhomocysteinemia as a risk factor for arterial and venous disease: of incidence and relevance. Thromb. Haemost., 1997, v.78, p. 520−522.
- Braun A., Muller Π., Rosche A. A. Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Hum. Genet., 1996, v. 97, p. 263−264.
- Brey R. L., Coull Π. M. Cerebral Venous Thrombosis: Role of Activated Protein Π‘ Resistance and Factor V Gene Mutation. Stroke, 1996, v. 27, p. 1719−1720.
- Broekmans A. W., Veltkamp J. J., Bertina R. M. Congenital protein Π‘ deficiency and venous thromboembolism: a study of three Dutch families. New Eng. J. Med., 1983, v. 309, p. 340−344.
- Brown Π. K., Luddington R., Williamson D., Baker P. Riskof venous thromboembolism associated with a G to A transition at position 20 210 in the 3'— untranslated region of the prothrombin gene. Brit. J. Haemotology, 1997, v. 98, p. 907−911.
- Bykowska K., Vertun-Baranowska Π., Windyga J. and Lopaciuk S. Prevalence of G20210A prothrombin gene mutation in Poland. Pol. Arch.Med. Wewn., 2002, v. 104(5), p. 729−733.
- Chaida C., Gialeraki A., Tsoukala C., Mandalaki T. Prevalence of FVQ 506 mutation in the Hellenic population. Thromb Haemost., 1996, v. 76, p. 127−131.
- Chan W. P., Lee Π‘. K., Kwong Y. L., Lam Π‘. K., Liang R. A novel mutation of arg306 of factor V gene in Hong Kong Chinese. Blood, 1998, v. 191, p. 11 351 139.
- Corral J., Zuaro-Jausoro J., Rivera R., Gonzalez-Conejero F. Clinical and analytical relevance of the combination of prothrombin 20 210 A/A and factor V Leiden: results from large family. Brit. J. Haemotology, 1999, v. 105, p. 560 563.
- Cosgriff Π’. M., Bishop D. Π’., Hershgold E. J., Skolnick M. H., Martin B. A., Baty B. J., Carlson K. S. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine, 1983, v. 62, p. 209−220.
- Couturaud F., Oger E., Abalain J.H., Chenu E., Guias Π., Floch H.H., Mercier Π., Mottier D. and Leroyer C. Methylenetetrahydrofolate reductase C677T genotype and venous thromboembolic disease. Respiration, 2000, v. 67(6), p. 657−661.
- Cumming A., Keeney S., Salden A., Bhavani M. The prothrombin gene 20 210 G-A: Prevalence in a U. K anticoagulant clinic population. Brit. J. Haemotology, 1997, v. 98, p. 566−569.
- Dahlback Π., Stenflo J. Binding ov bovine coagulation factor Xa to platelets. Biochemistry, 1978, v. 117, p. 4948−4951.
- Dahlback Π., Hildebrand B. Inherited resistance to activated protein Π‘ is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc. Nat. Acad. Sci., 1994, v. 91, p. 1396−1400.
- Dahlback Π., Hansson Π‘., Islam M., Szpirer J., Szpirer C,. Lundwall A., Levan
- G.Assignment of gene for coagulation factor V to chromosome 1 in man and to chromosome 13 in rat. Somat. Cell Molec. Genet., 1998, v. 14, p 509−514.
- De Bruijn S., Stam J., Koopman M., Vandenbroucke J. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Brit. Med. J., 1998, v. 316, p. 589−592.
- Debus O., Koch H., Kurlemann G., StraterR., Vielhaber H., Weber P., Nowak-Gottl U. Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. Arch. Dis. Child (Fetal Neonatal Ed.), 1998, v. 78, p. 121−124.
- Degen S. F., MacGillivray R. Π’., Davie E. W. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry, 1983, v. 22, p. 2087−2097.
- De Maat M., Bladbjerg E., Johansen L., Gram J., Jesperson .J. Absence of prothrombin mutation in Inuit. Thromb. Haemost., 1998, v. 79, p. 882- 883.
- Den Heijer M., Blom H., Gerrits W., Rosendaal F., Haak H., Wijermans P., Bos
- H. Is hyperhomocysteinaemia a risk factor for reccurent venous thrombosis?. Lancet, 1995, v. 345, p. 882−885.
- Den Heijer M., Koster Π’., Blom H., Bos H., Reitsma P., Rosendaal F. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Eng. J. Med., 1997, v. 334, p. 759−762.
- De Stefano V., Leone G. Antithrombin III congenital defects: revising classification system. Thromb. Haemost., 1989, v. 62, p. 820−821.
- Dimino G., Grandone E., Margaglione M. Clinical relevance of polymorfic markers of arterial thrombosis. Thromb. Haemost., 1997, v.78, p. 462−463.
- Eekhoff EM, Rosendaal FR, Vandenbroucke JP Minor events and the risk of deep venous thrombosis. Thromb Haemost., 2000, v. 83, p. 408−411.
- Egan Robert. Prothrombic and vascular risk factors in NAION. Ophthalmology, 2000, v. 107, p: 2116−2117.
- Egeberg O. Thrombophilia caused by inheritable deficiency of Blood antithrombin. Scand. J. Clin. Lab. Invest., 1965, v.17, p. 92−93.
- Engbersen A., Franken D., Boers G., Stevens E., Trijbels F., Blom
- H. Thermo labile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet., 1995, v. 56, p. 142−150.
- Fassett MJ, Bohn YC, Wing DA Longitudinal evaluation of activated protein Π‘ resistance among normal pregnancies of Hispanic women. Am J Obstet Gynecol 2000 Jun 182:6 1433−6.
- Fletcher O., Kessling A. MTHFR association wiTh arteriosclerotic vascular disease? Hum. Genet., 1998, v. 103, p. 11−21.
- Franco R. F,. Santos S.E., Elion J., TavellaM.H., Zago F. Prevalence of the G20210A Polymorphism in the 3-Untranslated Region of the Prothrombin Gene in Different Human Populations. Acta Haemotologica, 1998, v.100, p. 9−12.
- Franco R., Araujo A., Zago M., Elion. Analysis of the C677T mutation of the methylentetra hydrofolate reductase gene in different ethnic groups. Thromb and Haemost., 1998, v. 79, p. 119−121.
- Freeman J. M., Finkelstein J. D., Mudd S. H., Uhlendorf B. W. Homocystinuria presenting as reversible 'schizophrenia': a new defect in methionine metabolism with reduced methylene-tetrahydrofolate-reductase activity. Pediat. Res., 1972, v. 6, p. 423.
- Friedline JA., Ahmad E., Garcia D., Blue DD., CenizaN., Mattson JC. and Crisan D. Combined factor V Leiden and prothrombin genotyping in patients presenting with thromboembolic episodes. Arch. Pathol. Lab. Med., 2001, v. 125(1), p. 105−111.
- Gallus A. S. Familial venous thromboembolism and inherited abnormalities of the Blood clotting system. Aust. New Zeal. J. Med., 1984, v. 14, p. 807−810.
- Garsia-Gala J., AlvarezV., Pinto C., Soto I. Factor V Leiden (R506Q) and risk of venous thromboembolism: a case control study based on the Spanish population. Clin Genet., 1997, v. 152, p. 206−207.
- Gerhard A., Scharf R.E., Struve S., Zotz R.B. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. New. Engl. J. Med., 2000, v. 342, p. 374−380.
- Glueck C. J., Glueck H. I., Greenfield D., Freiberg R., Kahn A., Hamer Π’., Stroop D., Tracy T. Protein Π‘ and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediat. Res., 1994, v. 35, p. 383−388.
- Gomez E., Sonja C. Rapid Simultaneous Screening Of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood. Blood, 1997, v. 91, p. 2210−2211.
- Goyette P., Sumner J. S., Milos R., Duncan A. M. V, Rosenblat D. S., Matthews R. G., Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nature Genet., 1994, v. 7, p. 195−200.
- Goyette P,. Christensen Π., Rosenblatt D. S., Rozen R. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am. J. Hum. Genet., 1995, v. 59, p. 12 681 275.
- Goyette P., Pai A., Milos R., Frosst P., Tran P., Chen Z., Chan M., Rozen R. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome, 1998, v. 9, p. 652−656.
- Griffin J., Evat Π., Zimmerman Π’., Kleiss J., Wideman C. Deficiency of protein Π‘ in congenital thrombotic disease. J. Clin. Invest., 1981, v. 68, p. 1370−1373.
- Greer, A. The challenge of thrombophilia in maternal-fetal medicine. New Eng. J. Med., 2000, v. 342, p. 424−425.
- Greengard J., Sun X., Xu X., Fernandez J., Griffin J., Evatt B. Activated protein Π‘ resistance caused by arg506gln mutation in factor Va. Lancet, 1994, v. 343, p. 1361−1362.
- Greengard J., Eichinger S., Griffin J., Bauer K. Variability of thrombosis amonghomozygous siblings with resistance to activated protein Π‘ due to an arg-to-gln mutation in the gene for factor V. New Eng. J. Med., 1994, v. 331, p. 1559−1562.
- Gregg J. P., Yamane A. J., Grody W. W. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am. J. Med. Genet., 1997, v. 73, p. 334−336.
- Griffin A., Griffin H. Rapid DNA isolation. Current Innovations and Future., 1995, v. 32, p. 341−350.
- Gruenberg J. C., Smallridge R. C., Rosenberg R. D. Inherited antithrombin III deficiency causing mesenteric venous infarction: a new clinical entity. Ann. Surg., 1975, v. 181, p. 791−794.
- Grundy Π‘. Π., Holding S., Millar D. S., Kakkar V. V., Cooper D. N. A novel missense mutation in the antithrombin III gene (ser349-to-pro) causing recurrent venous thrombosis. Hum. Genet., 1992, v. 88, p. 707−708.
- Gurgey A., Mesci L. The prevalence of factor V Leiden mutation in Turkish population. Turk. J. Pediat., 1997, v.39, p. 37−39.
- Gurgey A., Balta G. and Boyvat A. Factor V Leiden mutations and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet’s disease. Blood Coagul. Fibrinolysis, 2003, v. 14(2), p. 121−124.
- Gurgey A., Hicsonmez G., Parlak H., Balta G. Prothrombin Gene 20 210 G-A mutation in Turkish Patients with Thrombosis. Am.J.Haemotology, 1998, v. 89, p. 179−200.
- Gyde Π. H., Middleton M. D., Vaughan G. R., Fletcher D. J. Antithrombin III deficiency, hypertriglyceridaemia, and venous thrombosis. Brit. Med. J., 1978, v. l, p. 621−622.
- Hillarp A je Zaller Π., Svrensson P.,. Dahlback B. The 20 210 G-A allele of the prothrombin gene is a common risk factor among Swidish outpatients with verified deep vein thrombosis. Thromb Haemost., 1997, v. 78, p. 990−996.
- Ho ward Π’.Π., Marusa M., Channell C., Duncan A. A patient homozygous for a mutation in the prothrombin gene 3-untranslated region associated with massive thrombosis. Blood Coagul Fibrinolysis., 1997, v. 8, p. 316.
- Hultin M. Π., Grimson R. C., Doggen Π‘. M., Rosendaal F. R., Cats V. M., Bertina R. M. Factor V Leiden, Prothrombin 20 210 Gene Variant, and Risk of Myocardial Infarction. Circulation, 1999, v. 99, p. 457−460.
- Humpert P. M., Isermann Π., Rudofsky G., Ziegler R., Bierhaus A., Ritz E., Nawroth P. P. The 20 210 G to A prothrombin polymorphism and late complications in type 1 diabetes mellitus.Thromb. Haemost., 1999, v. 81, No. 164, p. 64−67.
- Jenny R., Pittman D., Toole J., Kriz R., Aldape R., Hewick R., Kaufman R., Mann K. Complete cDNA and derived amino acid sequence of human factor V. Proc. Nac. Acad. Sci., 1987, v. 84, p. 4846−4850.
- Johnson E. J., Prentice Π‘. M., Parapia L. A. Premature arterial disease associated with familial antithrombin III deficiency. Thromb. Haemost., 1990, v. 63, p. 13−15.
- Juul, Tybjasrg-Hansen, Steffensen R., Kofoed S., Jensen G., and Nordestgaard. Factor Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood, 2002, v. 100, No. 1, p. 3−10.
- Kalafatis M., Rand M., Mann Π. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J.Biol.Chem., 1994, v. 269, p. 31 869−31 874.
- Kang S.-S., Wong P. K., Bock H.-G. O., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am. J. Hum. Genet., 1991, v.48, p. 546−551.
- Kang S.-S., Wong P. K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet., 1991, v. 48, p. 536−545.
- Kluijtsman L., den Heijer M., Reitsma P., Heil S., Blom H., Rosendaal F. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis.Thromb. Haemost., 1998, v. 79, p, 254−258.
- Kodaira H., Ishida F., Shimodaira S., Takamiya.O., Furihata K., Kitano K. Resistance to Activated Protein Π‘ and Arg 506 Gin Factor V Mutation are Uncommon in Eastern Asian Population. Acta Haemotologica, 1997, v. 981, p. 22−25.
- Koeleman B, Reitsma P, Allaart C, Bertina R. Activated protein Π‘ resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood, 1994, v. 84, p. 1031−1035.
- Kupferminc M., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A., Fait G., Lessing. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New Eng. J. Med., 1999, v. 340, p. 9−12.
- Lane D.A., Olds R. J., Thein S. L. Antithrombin III: summary of first database update. Nucleic Acids Res., 1994, v. 22, p. 3556−3559.
- Lane D. A., Grant P. J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000, v. 95, p. 1517−1532.
- Lanchantin G. F., Hart D. W., Friedmann J. A., Saavedra N. V., Mehl J. W. Amino acid composition of human plasma prothrombin. J. Biol. Chem., 1968, v. 243, p. 5479−5485.
- Lalouchek W., Aull W., Zeiler K. The Prothrombin G2021 OA Mutation and Factor V Leiden Mutation In Patients with Cerebrovaskular Disease.Blood., 1997, v. 87, p. 704−705.
- Lensen R.P., Bertina R. M. de Ronde H., Vandenbroucke J.P. and Rosendaal F.R. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb. Haemost., 2000, v. 83 (6), p. 817−821.
- Lensing A., Prandoni P., Prints M., Buller H. Deep-vein thrombosis. Lancet, 1999, v. 353, p. 479−485.
- Liang R., Lee Π‘. K., Wat M. S., Kwong Y. L., Lam Π‘. K., Liu H. W. Clinical significance of arg306 mutations of factor V gene. Blood, 1998, v. 92, p. 25 992 600.
- Lin J., She M., Tsay W. The mutation at position in the 3'-untraslated region is extremely rare in Taiwanese Chinese patients with venous thrombophilia. Thromb. Haemost., 1998, v. 80, p. 343.
- Lindqvist P., Svensson P., Dahlback Π., Marsal K. Factor V Q-506 mutation (activated protein Π‘ resistance) associated with reduced intrapartum Blood loss: a possible evolutionary selection mechanism. Thromb. Haemost., 1998, v. 79, p. 69−73.
- Mahmoud A., Elias E., Beauchamp N., WildeJ. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut., 1997, v. 40, p. 798 800.
- Maly J, Dulicek P, Safarova M Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian region. Clin. Appl. Thromb. Hemost., 2000, v. 6, No. 2, p. 87−89.
- Marciniak E., Farley Π‘. H., DeSimone P. A. Familial thrombosis due to antithrombin III deficiency. Blood, 1974, v. 43, p. 219−231.
- Margaglione M., D’Andrea G., Giuliani N., Brancaccio V., De Lucia D., Grandone E., De Stefano V., Tonali P. A., Di Minno G. Inherited Prothrombotic
- Conditions and Premature Ischemic Stroke: Sex Difference in the Association With Factor V Leiden. Arterioscler Thromb. Vase. Biol., 1999, v.19, p. 17 511 756.
- Markus H., Zhang Y., Jeffeiy S. Screening for the Factor-V Arg 506 Gin Mutation in Patients with TIA and Stroke. Cerebrovascular Diseases, 1996, v. 6, p. 360−362.
- Marlar R. A. Protein Π‘ in thromboembolic disease. Semin. Thromb. Hemost., 1986, v. 11, p. 387−393.
- Martinelli I., Sacchi E., Landi G., Taiol E., Duca F., Mannucci P. M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New Eng. J. Med., 1998, v.338, p. 1793−1797.
- Meinardi J.R., Pelsma P.M., Koning H., and van der Meer J. Double-Homozygosity for FactorV Leiden and the Prothrombin Gene G20210A Variant in a Young patient With idiopathic Venous Thrombosis. Blood, 1999, v. 94, No. 5, p. 1828−1829.
- McAndrew P., Brandt J., Pearl D., Prior T. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb. Res., 1996, v. 83, p. 195−198.
- Meinardi J. R., Pelsma P. M., Koning H., van der Meer J., Hamulyak K. Double-Homozygosity for Factor V Leiden and the Prothrombin Gene G20210A Variant in a Young Patient With Idiopathic Venous Thrombosis. Blood, 1999, v. 94, p. 1828−1829.
- Mercier G, Lucotte G. Population genetics of factor v leiden in Europe. Am. J. Reprod. Immunol., 2001, v. 45, p. 65−71
- Meyer M., Kutscher G., Vogel G. Simultaneous genotyping for factor V Leiden and prothrombin G20210A variant by a multiplex PCR-SSCP assay on whole Blood. Thromb. Haemost., 1999, v. 81, p. 162−163.
- Meyer-Michel S., Gerotziafas G., Conard J., Marie-Helene Horellou., Elalamy. Clinical Aspects and Laboratory Problems in Hereditary Thrombophilia. Haemostasis, 1999, v. 29, p. 76−99.
- Miyata Π’., Kawasaki Π’., Fujimura H., Uchida K., Tsushima M. The prothrombin gene G20210 mutation is not found among Japanese patients with thrombosis and healthy individuals. Blood Coagulation and Fibrinolysis, 1998, v. 9, p. 451−452.
- Motulsky A. G. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am. J. Hum. Genet., 1996, v. 58, p. 17−20.
- Nagayama Π’., Nagayama M., Tsuda M., Yoshii F., Shinohara.Y.Low Prevalence of Activated Protein Π‘ Resistance and Factor V Leiden in Ischemic Stroke in Japan. Cerebrovascular Diseases, 1996, v. 6, p. 356−359.
- Nishio H., Lee M., Fujii M., Kario K., Kayaba K., Shimada K., Matsuo M., Sumino K. A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population Jpn. J. Hum. Genet., 1996, v. 41, p. 247−251.
- Oner A. F., Arslan S., Caksen H., Ceylan A. Budd-Chiari syndrome in a patient heterozygous for both factor V Leiden and the G20210A mutation on the prothrombin gene. Thromb. Haemost., 1999, v. 82, p. 1366−1367.
- Ozbek N., Atac F.B., Verdi H. and Kayiran S.M. Purpura fulminans in a child with combined heterozygous prothrombin G20210A and factor V Leiden mutations. Ann. Hematol. 2003, v. 82, p. 118−120.
- Ozbek U., Tangun Y. Freguency of Factor V Leiden in Turkey. Br. J. Haemot., 1997, v. 97, p.504−505.
- Penick G. D. Blood states that predispose to thrombosis. In: Sherry S.- Brinkhous Π. M., Genton E., Stengle J. M. Thrombosis. Washington, D. C.: National Academy of Sciences (pub.) 1969.
- Pepe G., Riccards O., CamachoV., BrunneliT. Prevalence of factor V Leiden in Non-European populations. Thromb Haemost., 1997, v. 77, p .329−331.
- Perry D. J., Carrell R. W. Molecular genetics of human antithrombin deficiency. Hum. Mut., 1996, v. 7, p. 7−22.
- Prondiznski C., Wermes G., Sykora R. The prothrombin G20210 mutation detected by a PCR-based method in Patients with thrombosis. Conn Med., 1998, v. 62, p. 519−525.
- Ranguelov RD., Rosenthal N., Bromley C. and Vasef M.A. Detection of factor V Leiden and prothrombin gene mutations in patients who died with thrombotic events. Arch. Pathol. Lab. Med., 2002, v. 126(10), p. 1193−1996.
- Raziel A, Kornberg Y, Friedler S, Schachter M, Sela Π A, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am. J. Reprod. Immunol. Microbiol., 2001, v. 45, p. 62−71.
- Rees D.C., Cox M., Clegg J. World distribution of factor V Leiden. Lancet, 1995, v. 348, p. 1133−1134.
- Rees D. C., Chapman N. H., Webster M. Π’., Guerreiro J. F., Rochette J., Clegg J. B. Born to clot: the European burden. Brit. J. Haemat., 1999, v. 105, p. 564 566.
- Ridker P., Miletich J., Stampfer M., Goldhaber S., Lindpaintner K., Hennekens C. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 1995, v. 92, p. 2800−2802.
- Ridker P., Miletich J., Hennekens C., Buring J. Ethnic Distrebution of Factor V Leiden in 4047 Men and Women. JAMA., 1997, v. 277, p. 1305−1308.
- Rosendaal F., Siscovick D., Schwatrz R., Reitsma P. Factror V Leiden increases the risk of venous and artherial thrombosis in young women. Blood, 1997, v. 89, p. 2817−2818.
- Rosendaal F. R. Venous Thrombosis: Prevalence and Interaction of Risk Factors. Haemostasis, 1999, v. 29, p. 1−9.
- Rosendaal F. Venous Thrombosis: a multicausal disease. Lancet, 1999, v. 353, p. 1167−1173.
- Rosing J., Hoekema L., Nicolaes G. Effects or protein S and factor Xa and factor Va and factor Var506q by activated protein C. J. Biol.Chem., 1995, v. 270, p. 27 852−27 855.
- Royle N. J., Irwin D. M., Koschinsky M. L., MacGillivray R. T. A., Hamerton, J. L. Human genes encoding prothrombin and ceruloplasmin map to llpll-ql2 and 3q21−24, respectively. Somat. Cell Molec. Genet., 1987, v. 13, p. 285−292.
- Sarasin F., Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. Brit. Med. J., 1998, v. 316, p. 95−99.
- Schafer A. I. Venous thrombosis as a chronic disease. New Eng. J. Med., 1999, v. 340, p. 955−956.
- Schneider J. A., Rees D. C., Liu Y.-T., Clegg J. B. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am. J. Hum. Genet., 1998, v. 62, p. 1258−1260.
- Selingsohn U., Zavelin A. Thrombophilia as a multigenic disorder. Thromb. Haemost., 1997, v. 79, p. 297−301.
- Shen L., Dahlberg B. Factor V and protein S as synergistic cofactors to activated protein Π‘ in degradation of factor Villa. J. Biol. Chem., 1994, v. 269, p. 18 735−18 736.
- Sorja J,. Almasy L., Tirado L., Borell M. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood, 2000, v.95, p. 2780−2785.
- Svensson J., Dahlback B. Resistance to activated protein Π‘ as a basis for venous thrombosis. New Eng. J. Med., 1994, v. 330, p. 517−522.
- Sun X., Evatt Π., Griffin J. Blood coagulation factor Va abnormality associated with resistance to activated protein Π‘ in venous thrombophilia. Blood, 1994, v. 83, p. 3120−3125.
- Sykes T.F., Fegan C., Mosquera D. Thrombophilia, polymorphisms, and vascular disease. Mol. Pathol., 2000, v. 53, p. 300−306.
- Talmon Π’., Scharf J., Mayer E., Lanir N., Miller Π., Brenner B. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations. Am. J. Ophthal., 1997, v. 124, p. 689−691.
- Thorelli E., Kaufman R., Dahlberg B. Cleavege requirment for activation factor V by factor Xa. Eur. J. Biochemistry, 1997, v. 247, p. 12.
- Thorelli E., Kaufman R., Dahlback B. The C-terminal region of the FV B-domain is crucial for the anticoagulation for the anticoagulant activity of FV. J. Biol. Chem., 1998, v. 273, p. 169 148−169 155.
- Thorelli E., Randal J., Kaufman R., Dahlback B. Cleavege of Factor V at Arg 506 by Activated Protein Π‘ and the protein S. Π‘Π‘Π«ΠΠΠ
- Tripodi A., Chantarangkul V., Mannucci P. Hyperprothrombinemia may result in acquired activated protein Π‘ resistance. Blood, 2000, v. 96, p. 3295−3296.
- Voorberg J., Roelse J., Koopman R., Buller H., Berends F., ten Cate J., Mertens K., van Mourik A. Association of idiopathic venous thromboembolismwith single point-mutation at arg506 of factor V. Lancet, 1994, v. 343, p. 1 535 153 624.
- Wang H., Riddel D., Guinto E., MacGillivray R., Hamerton J. Localization of the gene encoding human factor V to chromosome lq21−25. Genomics, 1998, v. 2, p. 324−328.
- Wendel U., Bremer H. J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Europ. J. Pediat., 1984, v. 142, p. 147−150.
- Westendorp R., Reitsma P., Bertina R. Inherited prethrombotic disorders and infectious purpura. Thromb. Haemost., 1996, v. 75, p. 899−901.
- Williamson.D., Brown. K., Luddington R., Baglin C., Baglin T. Factor V Cambridge: a new mutation (arg306-to-thr) associated with resistance to activated protein C. Blood, 1998, v. 91, p. 1140−1144.
- Winter J. H., Fenech A., Ridley W., Bennett Π., Cumming A. M., Mackie M., Douglas A. S. Familial antithrombin III deficiency. Quart. J. Med., 1982, v. 51, p. 373−395.
- Zandra R., Lesly R., Chilcot I. The C677T MTHFRgene mutation is not predictive of risk for recurrent fetal loss. Brit. J. Haemotology., 1999, v. 1, p. 98−101.
- Zimmerman H., Cameron A., Fisher L. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis.H. Am. Coll. Cardiol., 1995, v. 26, p. 654−655.
- Zivelin A., Rosenberg N., Faier S., Kornbrot N., Peretz H. Mannhalter C,. Horellou M. H., Seligsohn U. A single genetic origin for the common prothrombotic G2021 OA polymorphism in the prothrombin gene. Blood, 1998, v. 92, p. 1119−1124.
- Zivelin A., Griffin H., Samama M., Eldor A. A single genetic origin for a common Caucasian risk Factor for venous thrombosis. Blood, 1997, v. 89, p. 397−401.
- Zoller Π., Dahlback Π. Linkage between inherited resistance to activated protein Π‘ and factor V gene mutation in venous thrombosis. Lancet, 1994, v. 343, p. 1536−1538.
- Zoller Π., Svensson P., He X., Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J. Clin. Invest., 1994, v. 94, p. 2521−2524.